Services

Online Inquiry

Your Name

Phone Number

* E-mail Address

* Services Interested

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Oligonucleotide Drugs CRO

At Protheragen BioNucleics, we are dedicated to revolutionizing the field of oligonucleotide therapeutics. With our comprehensive suite of Services, we leverage cutting-edge technology to accelerate drug discovery and development. Our mission is to provide end-to-end solutions that empower researchers and pharmaceutical companies worldwide to bring effective oligonucleotide drugs to market faster.

Overview of Oligonucleotide Drugs CRO

Oligonucleotide drugs represent a promising class of therapeutics capable of targeting genetic and molecular pathways that were previously considered undruggable. As a company specializing in oligonucleotide drugs, we offer a full spectrum of services from AI-powered sequence design to in vivo efficacy evaluation. Our expertise spans various oligonucleotide modalities, including siRNA, miRNA, antisense oligonucleotides (ASOs), and aptamers. By providing tailored solutions, we help our clients overcome the unique challenges associated with oligonucleotide drug development.

Our Services

AI-Powered Oligonucleotide Sequence Design Service

We utilize advanced artificial intelligence algorithms to design optimal oligonucleotide sequences with enhanced efficacy and minimized off-target effects. Our AI platform analyzes vast genomic datasets to predict the most effective sequences, streamlining the discovery process and increasing the likelihood of success in subsequent development stages.

Oligonucleotide Sequence Synthesis Service

Our oligonucleotide sequence synthesis service encompasses the production of high-quality oligonucleotide monomers and various specialized sequences, including small interfering RNA (siRNA), microRNA (miRNA), antisense oligonucleotides (ASOs), and aptamers. Each synthesis is conducted with precision to ensure optimal performance for therapeutic and research applications, meeting the rigorous demands of modern biotechnology.

Oligonucleotide Modification Service

Our oligonucleotide modification service focuses on enhancing the efficacy and stability of oligonucleotide therapeutics. We offer tailored modification options for siRNAs, miRNAs, ASOs, and aptamers, including chemical alterations like 2'-O-methylation and phosphorothioate backbones. These modifications are designed to improve cellular delivery, resistance to enzymatic degradation, and overall therapeutic potential.

siRNA Modification Service
miRNA Modification Service
ASO Modification Service
Aptamer Modification Service

Oligonucleotide Purification Service

Through our oligonucleotide purification service, we employ advanced techniques to ensure the purity of synthesized oligonucleotides. Our purification options include desalination, reversed-phase cartridge purification, high-performance liquid chromatography (HPLC), and polyacrylamide gel electrophoresis (PAGE). Each method is utilized to effectively separate full-length oligonucleotides from impurities, catering to stringent quality requirements in research applications.

Oligonucleotide Desalination Purification Service
Oligonucleotide Reversed-phase Cartridge Purification
Oligonucleotide HPLC Purification
Oligonucleotide PAGE Purification

Design and Optimization of Delivery Systems

In the design and optimization of delivery systems, we develop innovative solutions to improve the delivery of oligonucleotides to target cells. Our services include the development of GalNAc delivery systems for liver-targeting, peptide delivery systems for enhancing cellular uptake, and lipid and polymer nanoparticle (LNP and PNP) systems to protect oligonucleotides during circulation. Each delivery system is optimized for efficiency and specificity to maximize therapeutic effects.

GalNac Delivery System Development
Peptide Delivery System Development
Lipid Nanoparticle (LNP) Delivery System Development
Polymer Nanoparticle (PNP) Delivery System Development

Oligonucleotide Sequencing Service

Our oligonucleotide sequencing service provides comprehensive sequencing solutions, including Sanger sequencing for accurate verification, next-generation sequencing (NGS) for high-throughput data analysis, and single-molecule real-time sequencing for detailed examination of oligonucleotide characteristics. These services ensure that your

oligonucleotide sequences are accurate and functionally validated, supporting robust research and development initiatives.
Sanger Sequencing
Next-generation Sequencing (NGS)
Single-Molecule Real-Time Sequencing

Oligonucleotide Drug Bioanalysis

The oligonucleotide drug bioanalysis service offers thorough assessments of pharmacokinetics, toxicity, and immunogenicity related to oligonucleotide therapeutics. We perform pharmacokinetic analyses to evaluate drug absorption and distribution, while immunogenicity analyses detect potential antibody responses. Additionally, cytokine and biomarker analyses provide insights into the pharmacodynamic profiles, ensuring that your oligonucleotide drugs meet safety and efficacy standards.

Oligonucleotide Drug Pharmacokinetic/Toxicity Analysis
Immunogenicity Analysis
PD or TOX-related Cytokine and Biomarker Analysis

Oligonucleotide Drug In Vitro Efficacy Evaluation

Our oligonucleotide drug in vitro efficacy evaluation service is designed to assess the biological activity and effectiveness of oligonucleotide candidates in controlled environments. We carry out in vitro activity screening and verification, metabolite activity analysis, stability assessments, and off-target analysis. These evaluations provide critical data for optimizing therapeutic candidates and guiding further development.

In vitro Activity Screening and Verification
Metabolite Activity Analysis
Stability Analysis
Off-target Analysis

Oligonucleotide Drug In Vivo Efficacy Evaluation

We offer comprehensive in vivo studies using relevant animal models to evaluate the efficacy and safety of oligonucleotide drugs. Our services include pharmacodynamic assessments, biodistribution studies, and toxicity evaluations.

Frequently Asked Questions

Q1: What makes your AI-powered oligonucleotide design service superior?

Our AI-powered design service leverages advanced algorithms and machine learning to analyze vast genetic data. This enables us to predict highly effective oligonucleotide sequences with enhanced specificity and reduced off-target effects. By utilizing AI, we accelerate the design process and improve the success rate of candidate therapeutics.

Q2: What quality control measures do you implement for synthesized oligonucleotides?

We employ rigorous quality control measures throughout the oligonucleotide synthesis process. Each product undergoes physical and analytical testing, including high-performance liquid chromatography (HPLC) and mass spectrometry to confirm identity and purity. Additionally, we conduct sequencing verification for critical constructs to ensure accuracy and compliance with your specifications.

Q3: Can you assist with the characterization of oligonucleotide delivery systems?

Absolutely. Our team specializes in the characterization of oligonucleotide delivery systems, which includes evaluating encapsulation efficiency, release profiles, and stability under various conditions. We also assess the biological performance of these delivery systems in vitro to determine their efficacy in transporting oligonucleotides to target cells, ensuring that your therapeutic solutions meet the desired performance criteria.

Q4: What types of modifications can be made to oligonucleotides to improve their performance?

We offer a wide range of modifications to enhance the performance of oligonucleotides, including, but not limited to, 2'-O-methyl modifications, phosphorothioate linkages, and locked nucleic acids (LNAs). These modifications are designed to increase stability, reduce immunogenicity, improve binding affinity, and enhance cellular uptake, all contributing to a more effective therapeutic candidate.

Our services and products are exclusively for authorized organizations in research, development, or manufacturing and are not intended for direct use by individuals or patients or as medical advice, diagnosis, or treatment.